The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes

Hadassah Medical Organization50 enrolled

Overview

To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcumin and CoQ10 in MDS because these two agents possess many of the effects that are desirable in MDS.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Myelodysplastic Syndrome

Interventions

curcumin; coenzyme q10DRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long as their IPSS score ≤ 1.5. Exclusion Criteria: * Pregnant women and nursing women will be excluded. * History of clinically significant liver or kidney disease. * ECOG\>2 * IPSS score \>1.5 * Poorly controlled diabetes mellitus, hypertension, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.

Locations (1)

Hadassah Medical Organization

Jerusalem, Israel

Outcomes

Primary Outcomes

major hematologic improvement in any lineage

Secondary Outcomes

Time to disease progression

Overall and progression-free survival

Cytogenetic response

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.